Research programme: induced pluripotent stem cell-based allogeneic cytotoxic T cell therapies - Notch Therapeutics
Alternative Names: cytotoxic T cell therapy - Notch Therapeutics; iPSc-based allogenic cytotoxic T cell therapy - Notch TherapeuticsLatest Information Update: 13 Nov 2022
At a glance
- Originator Notch Therapeutics
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 14 Oct 2022 Preclinical study in Haematological malignancies in Canada (Parenteral) (Notch Therapeutics pipeline, October 2022).
- 14 Oct 2022 Preclinical study in Solid tumours in Canada (Parenteral) (Notch Therapeutics pipeline, October 2022)